System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Elisabetta Munzone is an expert in Oncology at European Institute of Oncology (Italy). As of October 2026, ScienceLeadR ranks Elisabetta Munzone in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Elisabetta Munzone has authored 227 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 9 of them ongoing. SLR score: 1,113 (community average: 125). How the SLR is computed.

LeadR Profile

Elisabetta Munzone European Institute of Oncology Italy
1 113 ScienceLeadR Reputation 1113

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Dermatology - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

European Institute of Oncology

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 227

Citations

Citations: 8 892 1st author: 36 Last author: 15 Unique author: 2

Main journals

Ann Oncol 23
J Clin Oncol 20
ESMO Open 17
Breast 15
Cancer Res 14

Best Journals

J Clin Oncol 6
Ann Oncol 5
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.
PMID 42872060 — hormones, therapeutics		EClinicalMedicine20260
CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer.
PMID 42856785 — breast neoplasms, neoplasms, biomarkers, breast, therapeutics		Res Sq20260
Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project.
PMID 42842547 — neoplasms, solutions, therapeutics, mental health		PLOS Digit Health20260
Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study.
PMID 42729525 — lymph nodes, breast neoplasms, neoplasms, cohort studies, hormones, lymph, breast		EClinicalMedicine20260
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.
PMID 42214155 — breast neoplasms, cyclin-dependent kinase 4, neoplasms, biomarkers, hormones, cyclin-dependent kinases, cyclins, breast, therapeutics		Breast20260

Clinical Studies 23

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 3

By phase:

N/A 8
Phase 3 8
Phase 2 7

By status:

Recruiting 10
Completed 6
Active not recruiting 4
Terminated 2
Unknown 1

By type:

Interventional 18
Observational 5

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 3
multicentricup10 13

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A proof of concept study to evaluate treatments efficacy by monitoring Minimal Residual Disease using ctDNA in HR positive HER2 negative early breast cancer population
2023-505661-89-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, proof of concept study, receptors, growth factor, breast, neoplasm, residual, therapeutics		Phase 2Recruiting2024
GIM27 THERapy a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER 2 Positive Breast Cancer Patients in Real World Setting
NCT07583485 — epidermal growth factor, marketing, growth, safety, breast neoplasms, pharmaceutical preparations, brain, neoplasms, neoplasm metastasis, receptors, growth factor, breast, protein-tyrosine kinases, tyrosine, therapeutics, capecitabine, trastuzumab		N/ARecruiting2024
Phase II study to test whether a combination of three drugs atezolizumab vinorelbine and weekly cyclophosphamide can activate T cells in patients with a specific type of advanced breast cancer called triple negative breast cancer
2024-514031-20-00 — cells, triple negative breast neoplasms, breast neoplasms, pharmaceutical preparations, cyclophosphamide, neoplasms, vinorelbine, breast, t-lymphocytes		Phase 2Recruiting2025
Toxicity Markers to Trastuzumab Deruxtecan (T DXd) In Patients With Advanced Breast Cancer
NCT07049133 — breast neoplasms, neoplasms, breast, trastuzumab		N/ARecruiting2025
EvoLution of Neoadjuvant TreatMent in Triple negative or HER 2 positive Breast Cancer Diagnosed in the EaRly Phase
NCT06894173 — breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS